958873-55-7Relevant academic research and scientific papers
The role of new technologies in defining a manufacturing process for ppara agonist ly518674
Argentine, Mark D.,Braden, Timothy M.,Czarnik, Jeffrey,Conder, Edward W.,Dunlap, Steven E.,Fennell, Jared W.,LaPack, Mark A.,Rothhaar, Roger R.,Scherer, R. Brian,Schmid, Christopher R.,Vicenzi, Jeffrey T.,Wei, Jeffrey G.,Werner, John A.,Roginski, Robert T.
supporting information; experimental part, p. 131 - 143 (2010/04/22)
The impact of several new technologies on the development of a manufacturing process for LY518674 is described. Extensive use of process analytical technology (PAT) throughout development, both at laboratory and pilot-plant scale, enabled data-rich experi
The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)- 5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist
Kou, Fengjiun,Clodfelter, Dean K.,Farid, Nagy A.,Wheeler, William J.,Mckendry, Lennon H.
, p. 693 - 701 (2008/02/10)
Although fenofibrate (1a) is commercially available and clinically effective in lowering serum triglycerides, its activity and sub-type selectivity at the PPARα receptors are only moderate; therefore, there exists a need for more potent and sub-type selec
